CLINICAL TRIAL: PI & PHARMACOKINETIC STUDY OF DRUG FOR SOLID TUMORS & LYMPHOMAS
CLINICAL TRIAL: PI & PHARMACOKINETIC STUDY OF DRUG FOR SOLID TUMORS & LYMPHOMAS
批准号:
7951280
负责人:
CHANDRA BELANI
金额:
$0.09万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2010-03-31
关键词:
AnimalsApoptosisClinical ResearchClinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseCutaneousDataDrug KineticsDrug usageEnzymesExcisionFunctional disorderFundingGoalsGrantHalf-LifeHepaticHistonesHourIn VitroInstitutionLymphomaLysineMetabolismMulticenter TrialsPathway interactionsPatientsPharmaceutical PreparationsPhaseProteinsRecurrent diseaseResearchResearch PersonnelResourcesSolid NeoplasmSourceSystemic TherapyT-Cell LymphomaUnited States National Institutes of HealthVorinostatcell growthinhibitor/antagonistneoplastic celltranscription factortumor growthtumor progression
中文摘要
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
This is a Phase 1, multicenter trial to determine the pharmacokinetic disposition of vorinostat is patients with varying degrees of hepatic dysfunction. Vorinostat is an inhibitor of Histone deacetylases (HDAC), enzymes that catalyze the removal of acetyl groups from the lysine residues of proteins, including histones and transcription factors. HDAC inhibitors can induce tumor cell growth arrest, differentiation, or apoptosis in vitro and inhibit tumor growth in animals and the eventual goal is to use this drug to treat solid tumors, and therefore tumor progression will be a secondary aim of the study. Vorinostat has recently been approved by the US FDA (400 mg PO QD) for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat has a short half life of less than 2 hours. The major pathways of metabolism of vorinostat involve glucuronidation and There are no data regarding the appropriate use of vorinostat in patients with hepatic dysfunction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: A PHASE I STUDY IN ADVANCED SOLID MALIGNANCIES (NCI 7967)
-
批准号:7951279
-
项目类别:
-
资助金额:$0.42万
-
财政年份:2009
-
负责人:CHANDRA BELANI
-
依托单位:
CLINICAL TRIAL: PI &PHARMACOKINETIC SINGLE AGENT STUDY OF DRUG IN PTS W ADV MALI
-
批准号:7951294
-
项目类别:
-
资助金额:$0.28万
-
财政年份:2009
-
负责人:CHANDRA BELANI
-
依托单位:
Phase I Clinical Trials of Novel Anticancer Agents
-
批准号:6878453
-
项目类别:
-
资助金额:$42.61万
-
财政年份:2003
-
负责人:CHANDRA BELANI
-
依托单位:
Phase I Clinical Trials of Novel Anticancer Agents
-
批准号:6581593
-
项目类别:
-
资助金额:$40.35万
-
财政年份:2003
-
负责人:CHANDRA BELANI
-
依托单位:
Phase I Clinical Trials of Novel Anticancer Agents
-
批准号:6722871
-
项目类别:
-
资助金额:$41.42万
-
财政年份:2003
-
负责人:CHANDRA BELANI
-
依托单位:
Phase I Clinical Trials of Novel Anticancer Agents
-
批准号:7021408
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2003
-
负责人:CHANDRA BELANI
-
依托单位:
PHASE I PHARMACOKINETIC STUDY OF CARBOPLATIN IN COMBO WITH WEEKLY PACLITAXEL
-
批准号:6304699
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:CHANDRA BELANI
-
依托单位:
FILGRASTIM SD/01 PTS W/ NON SMALL CELL LUNG CANCER OR THORACIC TUMORS
-
批准号:6304629
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1999
-
负责人:CHANDRA BELANI
-
依托单位:
FILGRASTIM SD/01 PTS W/ NON SMALL CELL LUNG CANCER OR THORACIC TUMORS
-
批准号:6264156
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:CHANDRA BELANI
-
依托单位:
PHASE I PHARMACOKINETIC STUDY OF CARBOPLATIN IN COMBO WITH WEEKLY PACLITAXEL
-
批准号:6219271
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1998
-
负责人:CHANDRA BELANI
-
依托单位:
PHASE I PHARMACOKINETIC STUDY OF CARBOPLATIN IN COMBO WITH WEEKLY PACLITAXEL
-
批准号:6275847
-
项目类别:
-
资助金额:$1.91万
-
财政年份:1997
-
负责人:CHANDRA BELANI
-
依托单位:
PHASE I STUDY OF DOCETAXEL AND CARBOPLATIN IN COMBINATION CHEMOTHERAPY
-
批准号:6245646
-
项目类别:
-
资助金额:$1.76万
-
财政年份:1997
-
负责人:CHANDRA BELANI
-
依托单位:
PHARMACOKINETIC STUDY OF TAXOL & CARBOPLATIN WITH FILGRASTIM IN LUNG CARCINOMA
-
批准号:6245696
-
项目类别:
-
资助金额:$1.76万
-
财政年份:1997
-
负责人:CHANDRA BELANI
-
依托单位:
FILGRASTIM FOR TREATMENT OF NONSMALL CELL LUNG CANCER OR THORACIC TUMORS
-
批准号:6266120
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1978
-
负责人:CHANDRA BELANI
-
依托单位:
PHASE I PHARMACOKINETIC STUDY OF CARBOPLATIN IN COMBO WITH WEEKLY PACLITAXEL
-
批准号:6114612
-
项目类别:
-
资助金额:$2.9万
-
财政年份:1978
-
负责人:CHANDRA BELANI
-
依托单位:
PHASE I/II PHARMACOKINETIC STUDY OF TAXOL AND CARBOPLATIN WITH FILGRASTIM
-
批准号:5218424
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:CHANDRA BELANI
-
依托单位:--
PHASE I STUDY OF DOCETAXEL AND CARBOPLATIN IN COMBINATION CHEMOTHERAPY
-
批准号:5218432
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:CHANDRA BELANI
-
依托单位:--
PHASE II STUDY OF IV ADMINISTERED TIRAPAZAMINE PLUS CISPLATIN IN NSCLC
-
批准号:5218404
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:CHANDRA BELANI
-
依托单位:--
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: